Coming soon for patients taking XARELTO® (rivaroxaban): Janssen CarePath for XARELTO® and Janssen Select will transition to XARELTO withMe. We are simplifying access to our patient support in one location with a new name and look. Savings card and coverage gap benefits will not change.
What is XARELTO®?
XARELTO® belongs to a group of medicines called direct oral anticoagulants, or DOACs for short. Like other DOACs, XARELTO® has no known dietary restrictions, no requirements for frequent blood tests, and few drug interactions.
How does XARELTO® work with aspirin?
Both XARELTO® and aspirin help prevent serious blood clots from forming and growing—but they work in different ways:
- XARELTO® slows your body's ability to clot by selectively blocking one of the clotting factors found in your blood—an enzyme called Factor Xa ("10a").
- Aspirin is an antiplatelet blood thinner that works by helping to keep platelets (which are pieces of blood cells) from sticking together and forming blood clots.
XARELTO® for people with CAD
XARELTO®, in combination with low-dose aspirin,* is the only drug in its class† indicated to help reduce the risk of heart attack, stroke, and cardiovascular death in adults with CAD.
*Low-dose aspirin = 75 mg-100mg once dialy.
†Direct oral anticoagulant (DOAC).
Almost 96% did not have
a cardiovascular
event‡
a cardiovascular
event‡
Almost 96% did not have a cardiovascular event‡
In a clinical trial,
almost 96% of the people did not have a heart attack or stroke, or die from a cardiovascular event.‡
‡The rate of the first event like a stroke, heart attack, or cardiovascular death was 4.2% for people taking XARELTO® plus low-dose aspirin vs 5.6% for low-dose aspirin alone. Patients were followed for an average of 23 months.
Remember, all blood thinners come with a risk of bleeding. Around 3% of people taking XARELTO® 2.5 mg twice daily in combination with low-dose aspirin experienced a major bleeding event, such as bleeding into the brain, compared to around 2% of people taking low-dose aspirin alone.